turn $10,000 into $1 million- but whcih stocks, page-83

Have a look at a Bio company called Giaconda GIA (Yes I own shares in this little gem of a company)

This company has been sitting below 10c for months now due to GFC and other factors.

The company is seeking funding for Myoconda, the company's lead product, is a combination of the antibiotics rifabutin, clarithromycin and clofazimine. The combination is envisaged as a new treatment for Crohn's Disease. This drug has the best results ever for Crohn's Disease sufferers.

Sales are estimated to be $US 2 Billion
Source: Page #11
http://www.giacondalimited.com/pdfs/AGM%20presentation.pdf

All this company requires is funding for the final stage. This was very close last year but GFC ended that. I spoke to the CEO 2 months ago and he is talking to US fund managers and is ‘Confident’ of future funding.

If funding is successful this baby will rocket due to the top 20 shareholders owning %90 of the stock.

Oh! has an excellent CEO..

NOTE: The below information is from a respected HC poster …..redned71

GIACONDA
Positives:
• Time from IPO to market is short (relative to newly-developed drugs) for both Myoconda and Heliconda, as both are at Phase III already. Myoconda has also completed phase IIIa, only IIIb to go. Heliconda has finished phase II & will enter phase III. This reduces the requirement to raise more funds through equity issues just to survive.
• Strategy to target the severe/chronic cases with nothing to lose by using these drugs should result in fast-track approval (but not guaranteed).
• Strategy re partners a very effective way to reduce costs.
• Experienced CEO – been there & done that, with a similar GI company in Canada & ran it to US$800m mkt cap. CDD a well-established business, with further drug combinations in the pipeline.
• All components drugs of Giaconda’s patented combinations are off patent.
• Margins will be very healthy (90%+) for Giaconda’s partners, ensuring attractive commercial deals with good up front payments, milestone payments & royalties.
• Inventor is NOT the CEO; the main failing of many Australian Pharma/Biotech start ups.
• “Rescue Therapy” company, working in areas where current therapies failing a good proportion of the market. “Meeting Unmet medical needs”
• Seems very attractively priced compared with other Australian listed Pharmaceutical companies (see page 3 of “Giaconda report”).

Negatives:
No friendly Gorilla/distribution system in place/No marketing partner has been signed up as yet.

However, discussions are at an advanced stage with at least one of the 24 companies contacted so far from the 41 targets identified in their global market search.
• efficacy shown to date;
• short time to market;
• using current proven drugs off patent;
• lower costs; high margins;
• great need to replace revenue/margin from many drugs coming off patent
• great market need – addressing severe end of their markets with high proportion failing current therapies
• all would suggest a strong probability in Giaconda being successful in finding their required partners to market their products. The deals Giaconda need to do are with the same companies that the CEO did 32 deals with at his previous Canadian company.



*Commercialisation Implementation
Licensing Strategy based upon
*Upfront fees + Royalties + Development
*Selection criteria
*Yielded target list of 41 companies in US, EU & Australia
*Met with 24 representing 20 countries
*All need new, patent protected products, now
Expectation is that these discussions will yield at least one partnership agreement within next 6-9 months that will begin to deliver early revenues to Giaconda.
They are going to some trouble to ensure they select partners that don’t have competing lines, but have a need & the marketing power to take their products successfully to market.




Wally…….